an unfavorable condition of the Company’s traditional trade channel because of the terminated contract with the distributor, which was effective since 30 June 2019. Further in this year, the period
following operation plans for Q2- Q4 to resolve such problems. 1. Focusing on the customer who has high-income, the company has been launching this plan since Q1/2018 and there is an increase of the size of
following operation plans for Q2- Q4 to resolve such problems. 1. Focusing on the customer who has high-income, the company has been launching this plan since Q1/2018 and there is an increase of the size of
0 1 8 but later terminated the contract with the distributor which is effective on 3 0 June 2 0 1 9 . During the period, the Company was unable to make any sales through traditional trade channel or
, The Company’s strategies such as increasing more specialty cilinics, medical instruments and expanding into new market so as to drive a sustainable growth Cost of Hospital Operations The costs of
30.69 1.90 6.21 Total revenue 1,151,091 1,374,128 (223,037) (16.23) 2,970,715 2,646,863 323,852 12.24 Total Cost & Expenses 1,013,853 1,243,461 (229,608) (18.47) 2,699,583 2,466,406 233,177 9.45 Selling
effective tax rate to decline to 15.8% Profit In 2020, EBITDA (pre-TFRS 16) was Bt76,619mn decreasing -2.7%YoY due to decline in revenue offset by cost control, with EBITDA margin of 44.3% compared to 43.5
decreased lease receivable, calculated according to the Effective Interest Method. 2.4 Cost of sales and rendering of services (excluding fuel costs) Cost of sales and rendering of services for the 2 nd
. Rathian Srimongkol as the Vice Chairman of the Board of Directors, effective from 12 October 2018. Appointed Prof. Dr. Surakiat Sathirathai as the Chairman of the Board of Directors and appointed Mr. Lee
May 2019. The Company still has fixed cost for the period of shutdown while doesn’t have sale revenue including cost per ton still high for production period which resulted from depreciation and the